



Department of Oncology
Mater Salutis Hospital
Legnago



Department of Public Health and
Community Medicine, Section of
Pharmacology, University of Verona



New York University
Medical School

**11th International Symposium on Platinum
Coordination Compounds in Cancer Chemotherapy**
Stem cells, DNA repair mechanisms, DNA-damaging agents



October 11-14, 2012

Verona - Italy

Final Programme

www.ispcc2012.it



Department of Oncology
Mater Salutis Hospital
Legnago



Department of Public Health and
Community Medicine, Section of
Pharmacology, University of Verona



New York University
Medical School

**11th International Symposium on Platinum
Coordination Compounds in Cancer Chemotherapy**
Stem cells, DNA repair mechanisms, DNA-damaging agents

October 11-14, 2012

**Palazzo della Gran Guardia, piazza Bra
Verona - Italy**

with the patronage of



European Society for Medical Oncology

(The 11th ISPPC has been awarded the ESMO Label and accredited with: 15, category 1, ESMO-MORA points)

and



Associazione Italiana
Oncologia Medica



Collegio Italiano Primari
Oncologi Medici Ospedalieri



Comune di
Verona



GOIRC
GRUPPO ONCOLOGICO ITALIANO
DI RICERCA CLINICA

Gruppo Oncologico Italiano di
Ricerca Clinica



Istituto Oncologico
Veneto



Società Italiana di
Chemioterapia



Regione
Veneto



Università di Verona

Scientific Committee

Franco Muggia, USA, *Chairman*

Alberto Amadori, Italy	Roberto Leone, Italy
Andrea Bonetti, Italy	Florian Lordick, Germany
Hilary A. Calvert, UK	Peter J. O'Dwyer, USA
Hernan Cortés-Funes, Spain	Paola Perego, Italy
Etienne Chatelut, France	Jacques Robert, France
Maurizio D'Incalci, Italy	Jan H.M. Schellens, The Netherlands
Nicholas P. Farrell, USA	Britta Stordal, Ireland
Stephen B. Howell, USA	Giampaolo Tortora, Italy

Local Organizing Committee

Andrea Bonetti and Roberto Leone, *Coordinators*

Emilia Durante	Ugo Moretti
Filippo Greco	Paolo Piacentini
Riccardo Lora	Michele Tognetto
Anna Mercanti	Anna Rita Trolese
Giacomo Moratello	Ermelinda Viola

Poster Prize Committee

Stephen B. Howell, USA
Roberto Leone, Italy
Jan H.M. Schellens, The Netherlands

Scientific Secretariat

Dept. of Public Health and Community Medicine, section of Pharmacology
"GB Rossi" University Hospital, piazzale LA Scuro 10, 37134 Verona, Italy
Phone: +39-0458124706, -0458027612; Fax: +39-0458124876
e-mail: info@ispcc2012.it


Organizing Secretariat and Travel Agency

Congress Dept. of RENBEL TRAVEL Srl
via Valpolicella 1, 37124 Verona, Italy
Phone: +39-0457701150; Fax: +39-045942022
e-mail: platinum@renbelgroup.it

VENUE FLOORPLAN

The ISPCC 2012 will be held at the "Palazzo della Gran Guardia", piazza Bra.

FIRST FLOOR



GENERAL INFORMATION

OFFICIAL LANGUAGE

The official language of the Symposium is English.

REGISTRATION DESK

The Registration Desk will be situated in the Foyer of the "Palazzo della Gran Guardia" and will be open at the following times:

Thursday 11th October 11.00-19.30

Friday 12th October 08.00-18.30

Saturday 13th October 08.00-19.00

Sunday 14th October 08.00-14.30

The Registration Desk can be reached by telephone or e-mail from Thursday 11th October. Tel: 348-5139626; e-mail: platinum@renbelgroup.it

SECURITY

Name badges **must** be worn at all times throughout the meeting. Delegates not wearing a name badge will be denied access to scientific sessions.

CLOAKROOM FACILITIES

Cloakroom facilities will be available in the ground floor for delegates to leave coats and luggage. The cloakroom will be staffed at the same times of the Registration Desk. Delegates leaving articles do so at **their own risk**.

MESSAGES

A message board where participants may leave messages and where messages will be placed for delegates will be situated next to the Registration Desk in the Foyer. Delegates are asked to check the board regularly for messages.

MOBILE TELEPHONES

As a courtesy to the speakers and other delegates, please ensure that mobile telephones are switched off during sessions.

SPEAKER PREVIEW

To ensure the smooth running of sessions, speakers are requested to report to the Slide Centre in the ground floor at least one hour before the start of their session to check their presentation with the technicians (please bring your presentation on an USB pen drive or CD-Rom Windows compatible). The Slide Centre will open at 11.00 a.m. on Thursday 11th October and remain open during the symposium hours.

COFFEE BREAK AND LUNCH

Mid-morning coffee, buffet lunch and afternoon coffee will be provided in the Shakespeare Gallery.

POSTER PRESENTATIONS

Poster presentations will be displayed in the Romeo and Juliet Hall as follows:

P.01a to P.29a: 11th–12th October

Posters can be mounted from 11.00 to 14.30 hours on Thursday 11th October. Posters must be removed within 18.30 hours on Friday 12th October.

P.01b to P.28b: 13th–14th October

Posters can be mounted from 08.00 to 09.00 hours on Saturday 13th October. Posters must be removed within 13.00 hours on Sunday 14th October.

Poster dimensions are: width 95 cm; height 95 cm.

Please refer to pages 15-19 for a list of the poster presentations.

Posters that are not removed by the time stated above will be removed by the Symposium Organizers and stored until the close of the symposium at 13.30 hours on Sunday 14th October.

Prizes will be awarded for the top three posters and prizes will be presented on Sunday 14th October during the Closing session starting at 13.00 hours.

ACCOMMODATION

For enquires relating to hotel accommodation which has been booked through the Organizing Secretariat, please go to the Registration Desk.

TOURIST BOARD

Delegates will be able to obtain information and leaflets on Verona attractions at the Registration Desk or at the Tourist Office, IAT via degli Alpini 9, near Palazzo della Gran Guardia; tel. +39-0458068680.

ECM (only for Italian delegates)

To obtain ECM credits delegates must sign daily (in & out) the attendance sheet at the Registration Desk and pass the evaluation test at the end of Symposium. Please remember to deliver the ECM forms at the Registration Desk at the end of the Symposium.

SOCIAL PROGRAMME

Welcome Cocktail

The Welcome Cocktail will be held at the "Palazzo della Gran Guardia" in the Shakespeare Gallery at 19.30 hours on Thursday 11th October. For admission to this event you must wear your name badge.

Social Dinner

The Social Dinner will take place at the "Piano Nobile" of "Palazzo della Gran Guardia" at 20.00 hours on Saturday 13th October. For admission you must present the yellow coupon which you received with your name badge.

SCIENTIFIC PROGRAMME

Thursday 11th October

WORKSHOP: STATE OF THE ART AND PERSPECTIVES OF CLINICAL CANCER RESEARCH IN THE VENETO REGION, THE RULES AND THE STAKEHOLDERS

Chairmen: Alberto Amadori, Istituto Oncologico Veneto, Padua, Italy
Giampaolo Velo, University of Verona, Verona, Italy

- 14.30-15.00 **European Community and Italian rules**
Michele Tognetto, Mater Salutis Hospital, Legnago, Italy
- 15.00-16.30 **The point of view of stakeholders**
The Pharmaceutical Industry
Gianni De Crescenzo, Pfizer, Italy
The Clinical Research Organisations
Silvia Sacchi, Quintiles, Italy
The Regional Regulatory Authorities
Giovanna Scroccaro, Servizio Farmaceutico, Regione Veneto, Italy
The Clinical Investigator
Andrea Bonetti, Mater Salutis Hospital, Legnago Italy
The Pharmacological Sciences Society
Domenico Criscuolo, Society for Applied Pharmacological Sciences, Italy
- 16.30-17.00 **Experiences from abroad**
Jan Schellens, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Franco Muggia, New York University, New York, USA
- 17.30-18.00 **OPENING OF THE 11TH ISPC**
Andrea Bonetti, Organizing Committee
Alessandro Mazzucco, Rector, University of Verona
Sandro Caffi, Managing Director, University Hospital of Verona
Daniela Carraro, Managing Director, ASL 21, Veneto Region
- 18.00-18.30
[O.01] **OPENING LECTURES**
**Platinum compounds: the next decade
or “The reports of my death are greatly exaggerated”**
Hilary Calvert, University of London, London, UK
- 18.30-19.00
[O.02] **Defective homologous recombination – the Achilles’ heel
of tumors to platinum treatment**
Jeff Boyd, Fox Chase Cancer Center, Philadelphia, USA

Friday 12th October

SESSION I: STEM CELL BIOLOGY GENETIC INSTABILITY, DNA REPAIR, AND PLATINUM RESISTANCE

Chairmen: Franco Bonetti, University of Verona, Verona, Italy
Jacques Robert, Institute Bergonie, Bordeaux, France

- 8.30-9.00
[O.03] **Control of the cellular pharmacology of cisplatin by copper transporters**
Stephen B. Howell, University of California, San Diego, USA
- 9.00-9.30
[O.04] **Resistance relationships between platinum and parp-inhibitors in ovarian cancer**
Britta Stordal, Trinity College, Dublin, Ireland
- 9.30-10.00
[O.05] **Therapeutic opportunity for transforming growth factor β in cancer therapy via DNA damage response and cancer stem cell renewal**
Mary H. Barcellos-Hoff, New York University, New York, USA
- 10.00-10.30
[O.06] **A platinum-induced fatty acid signalling network that protects tumors against chemotherapy**
Emile E. Voest, University of Utrecht, Utrecht, The Netherlands
- 10.30-11.00
[O.07] **Modulation of cell sensitivity to antitumor agents by targeting survival pathways**
Paola Perego, National Cancer Institute, Milan, Italy
- 11.00-11.30
Coffee, poster viewing
- 11.30-11.45
[O.08] **Combination of platinum and selected phytochemicals as a means to overcome resistance in ovarian cancer**
Fazlul Huq, University of Sydney, Sydney, Australia
- 11.45-12.00
[O.09] **Overcoming cisplatin-resistance by copper-lowering agents**
Macus T. Kuo, University of Texas MD Anderson Cancer Center, Houston, USA
- 12.00-12.15
[O.10] **Targeting nucleotide excision repair: chemical synthetic lethality and biology-based platinum-combination therapy**
John J. Turchi, Indiana University, Indianapolis, USA
- 12.15-12.30
[O.11] **Platinum-based cancer chemotherapeutics directly interact with STAT proteins and inhibit signaling by blocking the SH2 domain**
Stanleyson V. Hato, University of Amsterdam, Amsterdam, The Netherlands
- 12.30-12.45
[O.12] **Cisplatin-DNA-adducts in circulating tumor cells as "real-time" biomarkers of platinum resistance in non-small cell lung cancer**
Ann-Christin Nickel, University Hospital Essen, Essen, Germany

12.45-13.00 [O.13] **Impact of different KRAS mutations on cisplatin sensitivity in non-small-cell lung cancer**
Elisa Caiola, Mario Negri Institute for Pharmacological Research, Milan, Italy

13.00-14.00 *Lunch*

SESSION II: NEW AREAS OF CLINICAL RESEARCH WITH PLATINUMS, OTHER METALS, OTHER DNA DAMAGING AGENTS

Chairmen: Paola Perego, National Cancer Institute, Milan, Italy
Alberto Amadori, Istituto Oncologico Veneto, Padua, Italy

14.00-14.30 [O.14] **Immunogenic cell death of platinum compounds and radiation**
Encouse Golden, New York University, New York, USA

14.30-15.00 [O.15] **Beyond platinum: gold complexes as anticancer agents**
Dolores Fregona, University of Padua, Padua, Italy

15.00-15.30 [O.16] **Beyond platinum: ruthenium drug candidates**
Jan Schellens, The Netherlands Cancer Institute, Amsterdam, The Netherlands

15.30-15.45 [O.17] **Inhibition of the DNA damage response kinase, ATR, as a promising approach to increase the efficacy of cisplatin and other DNA damaging drugs**
John Pollard, Vertex Pharmaceuticals Ltd, Abingdon, UK

15.45-16.00 [O.18] **Targeting tumours with metal complexes**
Trevor W. Hambley, The University of Sydney, Sydney, Australia

16.00-16.30 *Coffee, poster viewing*

16.30-16.45 [O.19] **Nanosized hafnium oxide NBTXR3 and radiation as an innovative anticancer approach**
Agnès Pottier, Nanobiotix, Paris, France

16.45-17.00 [O.20] **New twists in aqueous cisplatin-nucleobase chemistry: cis-(NH₃)₂PtII as a catalyst, and easy conversion of one of its ammonia ligands into bridging amido ligands**
Bernhard Lippert, University of Dortmund, Dortmund, Germany

17.00-17.15 [O.21] **Mechanistic differences between a new platinum(II) mono-sulphonamide and cisplatin in melanoma cell lines**
José A. López-Martín, Hospital Universitario 12 de Octubre, Madrid, Spain

17.15-17.30 [O.22] **Major DNA adducts of the new anticancer azolato-bridged dinuclear platinum(II) complexes escape DNA repair mechanisms**
Viktor Brabec, Palacky University, Olomouc, Czech Republic

17.30-17.45 [O.23] **Liposomal cisplatin can overcome resistance of A2780 ovarian cancer cells – functional in vitro studies and search for underlying mechanisms by transcriptional profiling**
Gerd Bendas, University of Bonn, Bonn, Germany

- 17.45-18.00
[O.24] **Pd(II) and Pt(II) polyamine complexes as potential anticancer agents: cytotoxic activity towards human breast cancer**
Tânia M. Silva, University of Coimbra, Coimbra, Portugal
- 18.00-18.15
[O.25] **Metal-based anticancer agents basing on TCM active ingredients oxoaporphine**
Zhen-Feng Chen, Guangxi Normal University, Guilin, China
- 18.15-18.30
[O.26] **Combining platinum drugs with sorafenib: a promising strategy?**
Ganna V. Kalayda, University of Bonn, Bonn, Germany

Saturday 13th October

A TRIBUTE TO BARNETT ROSENBERG

- 8.30-8.45 [O.27] **Biography of Dr. Barnett Rosenberg: A tribute to his life and achievements**
James D. Hoeschele, Eastern Michigan University, Ypsilanti, USA
- 8.45-9.15 [O.28] **Memorial Lecture: Cisplatin and the revolution of treatment of germ cell tumors**
Lawrence H. Einhorn, Indiana University, Indianapolis, USA

SESSION III: NEW PLATINUMS AND NEW FORMULATIONS

Chairmen: Gianni Sava, University of Trieste, Trieste, Italy
Bernhard Lippert, University of Dortmund, Dortmund, Germany

- 9.15-9.45 [O.29] **Understanding and improving platinum anticancer drugs - phenanthriplatin**
Stephen J. Lippard, Massachusetts Institute of Technology, Boston, USA
- 9.45-10.15
[O.30] **Metalloglycomics: platinum and glycosaminoglycan (GAG), the extracellular DNA**
Nicholas P. Farrell, Virginia Commonwealth University, Richmond, USA
- 10.15-10.45
[O.31] **Multi-targeted precious metal anticancer complexes**
Peter Sadler, University of Warwick, Warwick, UK
- 10.45-11.15 *Coffee, poster viewing*
- 11.15-11.45
[O.32] **Targeted delivery and selective activation of platinum(II) anticancer complexes**
Zijian Guo, Nanjing University, Nanjing, China
- 11.45-12.00
[O.33] **Cellular and clinical studies of dicycloplatin, a new platinum compound approved by Chinese FDA for prostate cancer chemotherapy**
Jing J. Yu, West Virginia University, USA

- 12.00-12.15
[O.34] **New insights to the chemistry of Pt(IV) pro-drugs**
Dan Gibson, The Hebrew University, Jerusalem, Israel
- 12.15-12.30
[O.35] **Improved anticancer activity by cyclohexane ring-methylation of oxaliplatin Jungwirth**
Ute Jungwirth, University of Vienna, Vienna, Austria
- 12.30-12.45
[O.36] **Pt(IV) bis-, tris- and tetracarboxylato complexes as potential anticancer drugs: synthesis, analytical, biological, DFT and QSAR studies**
Hristo P. Varbanov, University of Vienna, Vienna, Austria
- 12.45-13.00
[O.37] **Reaction of platinum anticancer drugs and drug derivatives with a copper transporting protein, ATOX1**
Maria E. Palm-Espling, Umeå University, Umeå, Sweden
- 13.00-14.00 *Lunch*

SESSION IV: OPTIMIZING CLINICAL APPLICATIONS, WITH AN EMPHASIS ON NEW TARGETS

Chairmen: Giampaolo Tortora, University of Verona, Verona, Italy
Filippo de Braud, National Cancer Institute, Milan, Italy

- 14.00-14.30
[O.38] **Standardization of chemotherapy and individual dosing of platinum compounds**
Etienne Chatelut, Centre Claudius Regaud, Toulouse, France
- 14.30-15.00
[O.39] **Head and neck cancer**
Adriano Paccagnella, Ospedale dell'Angelo, Venice, Italy
- 15.00-15.30
[O.40] **Platinum drugs and DNA repair mechanisms in lung cancer**
Laura Bonanno, Istituto Oncologico Veneto, Padua, Italy
- 15.30-16.00
[O.41] **From platinum drugs to new targets and targeted therapies in advanced thoracic malignancies**
Ariel Lopez-Chavez, Knight Cancer Institute, Portland, USA
- 16.00-16.30 *Coffee, poster viewing*
- 16.30-17.00
[O.42] **Combining platinum drugs in treatment of gastrointestinal cancers**
Roberto Labianca, Ospedali Riuniti di Bergamo, Bergamo, Italy
- 17.00-17.30
[O.43] **Determinants of oxaliplatin sensitivity and resistance in colon cancer cells**
Peter O'Dwyer, University of Pennsylvania, Philadelphia, USA
- 17.30-18.00
[O.44] **The resurgence of platinum drugs in the treatment of breast cancer**
Judy Garber, Dana Farber Cancer Institute, Boston, USA

- 18.00-18.15
[O.45] **Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancer**
Godefridus J. Peters, VU University Medical Center, Amsterdam, The Netherlands
- 18.15-18.30
[O.46] **A panel of four gene polymorphisms involved in platinum/radiation resistance predicts survival in esophageal cancer**
Milena Gusella, ASL-18, Rovigo, Italy

Sunday 14th October

SESSION V: OPTIMIZING CLINICAL APPLICATIONS AND LOCO-REGIONAL THERAPIES FOR PERITONEAL MALIGNANCIES

Chairmen: Giovanni De Manzoni, University of Verona, Verona, Italy
Silvano Brienza, Debiopharm S.A., Lusanne, Switzerland

- 8.30-8.50
[O.47] **Treatment implications of ovarian cancer tumor biology: focus on BRCA function and intraperitoneal cisplatin**
Franco Muggia, New York University, New York, USA
- 8.50-9.10
[O.48] **Endometrial cancer**
Cristiana Sessa, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- 9.10-9.30
[O.49] **Novel strategies for getting more drug to intraperitoneal tumors**
Stephen B. Howell, University of California, San Diego, USA
- 9.30-9.50
[O.50] **HIPEC: an added value to intraperitoneal chemotherapy?**
Franco Roviello, University of Siena, Siena, Italy
- 9.50-10.05
[O.51] **Symptomatic treatment for malignant ascites: the trifunctional antibody catumaxomab**
Jan Braess, Clinic for Oncology and Haematology Barmherzige Brüder Regensburg, Regensburg, Germany
- 10.05-10.20
[O.52] **BRCA mutations outcome and platinum sensitivity in epithelial ovarian cancer: experience in ethnically diverse populations**
Tamar Safra, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- 10.20-10.35
[O.53] **Pharmacokinetics during intraoperative hyperthermic intraperitoneal chemoperfusion with cisplatin in patients with platinum-sensitive recurrent epithelial ovarian cancer: preliminary results**
Maximilian Kullmann, University Hospital Bonn, Bonn, Germany
- 10.35-11.00 *Coffee, poster viewing*

SESSION VI: STRATEGIES FOR TOXICITY REDUCTION AND IMPROVING THERAPEUTIC INDEX

Chairmen: Maurizio D'Incalci, Istituto Mario Negri, Milan, Italy

Hernan Cortes-Funes, Hospital Universitario 12 de Octubre, Madrid, Spain

11.00-11.25
[O.54]

An update on chemotherapy-induced neurotoxicity

Guido Cavaletti, University of Milan "Bicocca", Monza, Italy

11.25-11.50
[O.55]

Management of chemotherapy induced nausea and vomiting

Fausto Roila, Terni Hospital, Terni, Italy

11.50-12.15
[O.56]

Saving ears and kidneys from cisplatin

Giuliano Ciarimboli, University of Munster, Munster, Germany

12.15-12.30
[O.57]

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four western studies

Katsushige Gomi, Yakult Honsha Co Ltd, Japan

12.30-12.45
[O.58]

Targeting drug transporters in critical physiological cells to eliminate the major side effects of cisplatin: a mouse study

Jürgen Thomale, University of Duisburg-Essen, Essen, Germany

12.45-13.00
[O.59]

Skin tests protocol for the prevention of hypersensitivity reactions to oxaliplatin

Mauro Pagani, Azienda Ospedaliera C. Poma, Mantova, Italy

13.00-13.30

POSTER PRIZE AWARDS AND CLOSE OF ISPCC 2012



POSTER PRESENTATIONS

Please note that the numbers listed correspond to the numbers of the poster boards in the Romeo and Juliet Hall.

SESSION I

Thursday 11th – Friday 12th October

- P.01a Pharmacological modulation of *in vitro* cell response to cisplatin and *trans*-[PtCl₂(4-acetylpyridine)₂] in cisplatin resistant A549 cells
Arandelović S, Gligorijević N, Filipović L, Krivokuća A, Janković R, Rakić G, Tešić Ž, Radulović S
- P.02a Comparison of activity and mechanism of action of *trans*-platinum(II) and *trans*-platinum(IV) complexes with acetylpyridine ligands on the endothelial cell line EA.hy926
Filipovic L, Rakic G, Krivokuca A, Arandelovic S, Gligorijevic N, Radulovic S
- P.03a *In vitro* combination study of picolinate ruthenium(II)-p-cymene complex with cisplatin or paclitaxel
Gligorijević N, Arandelović S, Radulović S
- P.04a Overcoming platinum resistance: triggering the extrinsic apoptotic pathway
Romero I, Qamar B, Hearn J, Fu Y, Sadler PJ
- P.05a Transport of *N7*-platinated purines across *HeLa* cells plasma membrane
Girelli CR, Benedetti M, Migoni D, Romano A, Verri T, Fanizzi FP
- P.06a Cisplatin and *trans*-palladiums are found to act synergistically in ovarian cancer cell lines
Mazumder MEH, Beale P, Chan C, Yu JQ, Huq F
- P.07a Platinums and phytochemicals – in sequenced combination to overcome chemo-resistance in cancer treatment
Nessa MU, Beale P, Chan C, Yu JQ, Huq F
- P.08a Aiming to maximise antitumour activity of platinum drugs in ovarian tumour models
Al-Eisawi Z, Beale P, Chan C, Yu JQ, Huq F
- P.09a Enhancing platinum drug action due to combination with selected phytochemicals in human ovarian tumour models
Althurwi S, Yu JQ, Beale P, Chan C, Huq F
- P.10a Anti-metastatic activity of Pd(II)-spermine toward human breast cancer
Batista de Carvalho ALM, Marques MPM
- P.11a Pt(II) and Pd(II) polyamine complexes as promising anticancer approaches towards metastatic prostate cancer
Matos CS, Batista de Carvalho ALM, Marques MPM

- P.12a Collateral sensitivity to cisplatin in KB-8-5-11 is confluence dependant
Lawlor D, O'Leary JJ, Stordal B
- P.13a Developing platinum and taxane resistant ovarian cancer cell lines: investigating the role of BRCA1
Busschots S, O' Toole S, Hennessey BT, O'Leary JJ, Stordal B
- P.14a Repair mechanisms of cisplatin induced DNA modifications in mice
Ziehe M, Ruhe L, Rausch R, Thomale J, Linscheid MW
- P.15a Characterization of a cisplatin-DNA-antibody and its corresponding antibody-antigen-complexes by mass spectrometry under native conditions
Hochkirch U, Hofmann J, Thomale J, Linscheid MW
- P.16a Alterations of the mitogen-activated protein kinase pathway in ovarian carcinoma cells resistant to platinum compounds
Cossa G, Lanzi C, Gatti L, Cassinelli G, Carenini N, Zunino F, Zaffaroni N, Perego P
- P.17a Cell death enhancement after irradiation with monochromatic synchrotron X-rays at platinum K-edge in cisplatin pre-treated human non small cell lung cancer, ovarian and stem glioma cells
Ceresa C, Nicolini G, Bravin A, Requardt H, Le Duc G, Cavaletti G
- P.18a An implantable platinum based hydrogel for the treatment of cancer
Oun R, Plumb JA, Wheate NJ
- P.19a Characteristics of mitochondria in platinum resistant human ovarian carcinoma cells
Isonishi S, Morikawa A, Seki T, Ueda K, Saito M, Saito M, Suzuki K, Yanagida S
- P.20a Antitumor activity of liposomal cisplatin (Lipoplatin) on cisplatin-sensitive and -resistant ovarian cancer cells and xenografts
Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D
- P.21a The thermodynamics of translesion DNA synthesis past major adducts of enantiomeric analogs of antitumor cisplatin
Malina J, Novakova O, Natile G, Brabec V
- P.22a Insight into the anti-cancer activity of the platinum-histone deacetylase inhibitor conjugate, *cis*-[Pt(NH₃)₂malSAHA-_{2h}]
Brabec V, Griffith DM, Kisova A, Kosthunova H, Zerkankova L, Marmion CJ, Kasparkova J
- P.23a Interactions of DNA with a new anticancer platinum(IV) complex photoactivated by UVA and visible light
Pracharova J, Zerkankova L, Stepankova J, Novakova O, Farrer NJ, Sadler PJ, Brabec V, Kasparkova J
- P.24a Molecular mechanism of resistance to cisplatin: study of metabolism in ovarian cancer cells
Catanzaro D, Montopoli M, Bellanda M, Ragazzi E, Froidi G, Mammi S, Caparrotta L

- P.25a The role of wild-type p53 in the cisplatin-induced DNA damage-repair pathway and new strategies to overcome drug resistance in ovarian cancer treatment
Yu JJ, Liang XB, Yan BX, Guo Y, Mueller MD
- P.26a Cisplatin interplay with guanine. A molecular view
Lopes RP, Marques MPM, Valero R, Tomkinson J, Batista de Carvalho LAE
- P.27a Synthesis, characterization, in vitro activity against human ovarian tumour models of trans-platinum complex with acetate leaving groups
Fasim E, Beale P, Chan C, Yu JQ, Huq F
- P.28a *In vitro* properties of two water soluble heavy metal-based complexes
Nicolini G, Ceresa C, Gandin V, Porchia M, Pellei M, Santini C, Cavaletti G
- P.29a *In vivo* effect of copper status indexes on cisplatin distribution and its nephrotoxic effects in mice
Skvortsov AN, Rusconi P, Tsymbalenko NV, Puchkova LV, Brogini M

SESSION II

Saturday 13th – Sunday 14th October

- P.01b Human mesenchymal stem cells protection on cisplatin-treated dorsal root ganglia
Ravasi M, Maggioni D, Milano A, Monfrini M, Donzelli E, Foudah D, D'Amico G, Miloso M, Scuteri A, Tredici G
- P.02b A longitudinal study on oxaliplatin induced peripheral neuropathy – incidence and facts about the “real life” population and actual dose
Alberti P, Cortinovis D, Cazzaniga M, Bidoli P, Cavaletti G
- P.03b Characterization of peripheral neuropathy induced by chronic cisplatin administration in several mice models
Sala B, Carozzi VA, Chiorazzi A, Meregalli C, Oggioni N, Canta A, Cavaletti G
- P.04b Stress-kinase response to cisplatin, oxoplatin and titanocene Y in NCI-H-526 small cell lung cancer cells
Olszewski U, Tacke M, Hamilton G
- P.05b Rhenium porphyrin conjugates with photoactivable features
Bergamo A, Spagnul C, Gianferrara T, Alessio E, Alberto R
- P.06b The pros and the cons of ruthenium complexes: hits or leads of a new generation of anticancer metal-based drugs?
Sava G, Bergamo A
- P.07b Studies on new platinum compounds structurally and functionally different than cisplatin
Arzuman L, Huq F, Yu JQ, Beale P

- P.08b Synergistic interaction between histone deacetylase inhibitors and bortezomib in ovarian carcinoma cells
Gatti L, Benedetti V, De Cesare M, Corna E, Zaffaroni N, Zunino F, Perego P
- P.09b Photoactivated platinum anticancer complexes: novel mechanism of action
Butler JS, Woods JA, Farrer NJ, Newton ME, Sadler PJ
- P.10b Phase II study of panitumumab in combination with FOLFOXIRI as first-line treatment in molecularly selected metastatic colorectal cancer patients
Fornaro L, Lonardi S, Loupakis F, Masi G, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Fontanini G, Zaniboni A, Aprile G, Zagonel V, Falcone A
- P.11b FOLFOXIRI plus bevacizumab as first-line treatment of *BRAF* mutant metastatic colorectal cancer patients
Salvatore L, Loupakis F, Cremolini C, Schirripa M, Masi G, Antoniotti C, Fornaro L, Sensi E, Lupi C, Bergamo F, Lonardi S, Zagonel V, Fontanini G, Falcone A
- P.12b Clinical outcome according to p16 status and evaluation of concomitant treatment toxicity in oropharyngeal cancer patients
Valduga E, Caldara A, Vanoni V, Magri E, Bolner A, Vattei E, Bragantini E, Grandi C, Tomio L, Galligioni E
- P.13b Chemistry and biological activity of platinum amidine complexes
 Michelin RA, Sgarbossa P, Bertani R, Gandin V, Marzano C
- P.14b Development of radioactive cisplatin for the evaluation of the timing and dosing of the drug by molecular imaging
Codée-van der Schilden K, Zwaagstra O, Charlton K
- P.15b Moving the paradigm in platinum-based chemotherapy from Pt(II) to Pt(IV) complexes?
 Osella D, Ravera M, Gabano E, Zanellato I, Bonarrigo I, Alessio M, Bianco S
- P.16b Metalated purines as a new possible path to antitumor and antiviral drugs
Benedetti M, Girelli C, Romano A, Carrisi C, Lunetti P, Antonucci D, Migoni D, Verri T, Capobianco L, Fanizzi FP
- P.17b Synthesis and antitumoral evaluation of *trans* platinum diiodido complexes with aliphatic and aromatic amines
 Parro T, Cabrera S, Cubo L, Carnero A, Perles J, Navarro-Ranninger C, Quiroga AG
- P.18b A case of poor prognosis non-seminomatous germ cell tumor presenting with extremely high levels of human chorionic gonadotropin levels
Piacentini P, Remo A, Greco F, Mercanti A, Rubin L, De Fanti M, Bonetti A
- P.19b A case of relapse of stage i testicular non-seminomatous-germ-cell-tumor occurring > 10 year after orchifuniculectomy and retroperitoneal lymph-node dissection
Greco F, Mercanti A, Idili A, Trolese A, Durante E, Piacentini P, Bonetti A

- P.20b Neurophysiological assessment of advanced colorectal cancer patients treated with oxaliplatin
Del Colle R, Ferigo L, Mercanti A, Bonometti MA, Greco F, Bonetti A, Polo A
- P.21b Platinum-based chemotherapy for advanced non small cell lung cancer in elderly (≥ 70 years) patients.
Piacentini P, Greco F, Mercanti A, Trolese AR, Durante E, Bonetti A
- P.22b Trans configured bis(oxime)platinum(II) complexes: structure-activity relationships and DNA damage
 Bartel C, Flocke L, Scaffidi-Domianello YY, Jakupec MA, Galanski M, Keppler BK
- P.23b The use of oxaliplatin as an alternative therapy for high-grade prostate cancer: identification of serine hydroxymethyl transferase 2 (SHMT2) as a specific marker of oxaliplatin response
 Puyo S, Houédé N, Kauffmann A, Richaud P, Robert J, Pourquier P
- P.24b New platinum(II) mono-sulphonamides as novel antitumoral agents
 Díaz-García V, Pérez C, Agudo-López A, del Solar V, Agulló-Ortuño MT, Cortés-Funes H, Navarro-Ranninger C, Alemán J, López-Martín JA
- P.25b Synthesis and in vitro antitumor activity of two particularly stable trans-Pt(IV) complexes bearing aliphatic amines and phosphine ligands
 Medrano MA, Álvarez-Valdés A, Carnero A, Perles J, Navarro-Ranninger C, Quiroga AG
- P.26b A pathological evaluation of peritoneal carcinomatosis
 Guerini F, Giacomuzzi S, Zanoni A, Di Cosmo MA, Weindelmayer J, Caldana M, de Manzoni G
- P.27b Long-term outcomes of platinum-based chemotherapy in patients with stage II-III germ cell tumors: a single-center 30-year experience
De Velasco G, Castellano D, Sepulveda JM, Villacampa F, Pascual T, Manneh R, Parrilla L, Blázquez M, Ghanem I, Cortés-Funes H
- P.28b Weekly carboplatin plus paclitaxel plus cetuximab (Carbitax) novel combination chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: retrospective analysis of a single institution
Iglesias L, Nuñez JA, Ghanem I, Hoyos S, Vega E, Parrilla L, Blázquez M, Cortes-Funes H



SPONSORSHIPS

The Organizers are grateful to the following Companies who have contributed to the organization of ISPCC 2012:

AMGEN® Dompé

 **Bayer HealthCare**

B|BRAUN
SHARING EXPERTISE

BIC *Medical Europe S.r.l.*
We care for your life

**Celgene**



CREDIVENETO
CREDITO COOPERATIVO

 **GlaxoSmithKline**
Oncology

 **FRESENIUS**
BIOTECH

Janssen
PHARMACEUTICAL COMPANIES
of Johnson-Johnson

**MERCK**
MerckSerono
Living science, transforming lives

Con il supporto non condizionato di
MSD ITALIA S.R.L. www.msd-italia.it  **MSD**

**Mitt**
PRO

 **nano** BIOTIX


NOEMALIFE
WE CARE

 **NOVARTIS**
ONCOLOGY

 **Pfizer** **Oncology**

Pharma
Mar
Grupo Zeltia


Pierre Fabre
Pharma

 **QUINTILES®**


Roche
We Innovate Healthcare

SANOFI 

STIZZOLI

**Takeda**

**TEVA**